Intra-Cellular Therapies Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Intra-Cellular Therapieshan disminuido a un ritmo medio anual de -10.9%, mientras que en la industria Pharmaceuticals los ingresos han sido de growing a 6.5% anuales. Los ingresos han sido growing a una tasa media anual de 76%.
Información clave
-7.3%
Tasa de crecimiento de los beneficios
4.8%
Tasa de crecimiento del BPA
Crecimiento de la industria Pharmaceuticals | 6.0% |
Tasa de crecimiento de los ingresos | 73.1% |
Rentabilidad financiera | -23.6% |
Margen neto | -30.1% |
Última actualización de beneficios | 31 Dec 2023 |
Actualizaciones de resultados anteriores recientes
Recent updates
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark
Apr 09We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Mar 17Intra-Cellular Therapies Is On Fire
Mar 11Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
Feb 11Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues
Dec 24We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Nov 11Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth
Aug 07Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation
May 09After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar
Apr 17We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Jan 31Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans
Oct 25Intra-Cellular Therapies: What Lies Ahead
Sep 20Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug
Aug 22Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M
Aug 09We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Jul 09Intra-Cellular Therapies: A Dramatic Story
Jun 18Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth
Apr 03Intra-Cellular: Not Participating In A Bear Market
Mar 31Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand
Mar 08We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Dec 24Intra-Cellular's Second FDA Win Makes It A Great Long-Term Investment
Dec 21Intra-Cellular Therapies: A Leader In The Psychiatric Medicine Space
Nov 08We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Aug 06We Think The Compensation For Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Looks About Right
Jun 15Intra-Cellular Therapies (ITCI) Presents At RBC Capital Markets Global Healthcare Conference - Slideshow
Jun 04FDA accepts Intra-Cellular Therapies' lumateperone applications for bipolar depression
May 03Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Intra-Cellular Therapies. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
31 Dec 23 | 464 | -140 | 410 | 0 |
30 Sep 23 | 420 | -155 | 400 | 0 |
30 Jun 23 | 366 | -184 | 383 | 0 |
31 Mar 23 | 311 | -228 | 382 | 0 |
31 Dec 22 | 250 | -256 | 359 | 0 |
30 Sep 22 | 188 | -298 | 344 | 0 |
30 Jun 22 | 138 | -321 | 326 | 0 |
31 Mar 22 | 103 | -304 | 295 | 0 |
31 Dec 21 | 84 | -284 | 273 | 0 |
30 Sep 21 | 71 | -259 | 251 | 0 |
30 Jun 21 | 56 | -237 | 233 | 0 |
31 Mar 21 | 38 | -232 | 205 | 0 |
31 Dec 20 | 23 | -227 | 186 | 0 |
30 Sep 20 | 10 | -207 | 151 | 0 |
30 Jun 20 | 3 | -187 | 113 | 0 |
31 Mar 20 | 1 | -160 | 87 | 0 |
31 Dec 19 | 0 | -148 | 65 | 0 |
30 Sep 19 | 0 | -148 | 51 | 0 |
30 Jun 19 | 0 | -155 | 44 | 0 |
31 Mar 19 | 0 | -154 | 35 | 0 |
31 Dec 18 | 0 | -155 | 30 | 0 |
30 Sep 18 | 0 | -145 | 27 | 0 |
30 Jun 18 | 0 | -126 | 24 | 0 |
31 Mar 18 | 0 | -106 | 24 | 0 |
31 Dec 17 | 0 | -98 | 24 | 0 |
30 Sep 17 | 0 | -95 | 25 | 0 |
30 Jun 17 | 0 | -102 | 26 | 0 |
31 Mar 17 | 0 | -116 | 26 | 0 |
31 Dec 16 | 0 | -116 | 25 | 0 |
30 Sep 16 | 0 | -118 | 24 | 0 |
30 Jun 16 | 0 | -120 | 22 | 0 |
31 Mar 16 | 0 | -110 | 19 | 0 |
31 Dec 15 | 0 | -105 | 18 | 0 |
30 Sep 15 | 0 | -91 | 15 | 0 |
30 Jun 15 | 0 | -65 | 14 | 0 |
31 Mar 15 | 0 | -48 | 12 | 0 |
31 Dec 14 | 1 | -31 | 10 | 0 |
30 Sep 14 | 1 | -24 | 9 | 0 |
30 Jun 14 | 2 | -22 | 8 | 0 |
31 Mar 14 | 2 | -26 | 7 | 0 |
31 Dec 13 | 3 | -27 | 6 | 0 |
30 Sep 13 | 3 | -20 | 4 | 0 |
30 Jun 13 | 2 | -17 | 4 | 0 |
Ingresos de calidad: ITCI actualmente no es rentable.
Margen de beneficios creciente: ITCI actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: ITCI no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 10.9% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de ITCI en el último año con su media de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: ITCI no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Pharmaceuticals (-3.2%).
Rentabilidad financiera
Alto ROE: ITCI tiene un Rendimiento de los fondos propios negativo (-25.82%), ya que actualmente no es rentable.